EU to terminate vaccine agreement with Valneva

A lacking marketing approval has allowed the European Commission to terminate its Covid-19 vaccine purchasing agreement with Valneva.

Photo: David Vincent/AP/Ritzau Scanpix

On Monday, French vaccine maker Valneva is being punished by investors on the Paris stock exchange following news that the EU is intending to terminate its purchasing agreement on Covid-19 vaccines.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs